Pericardiocentesis and systemic cytotoxic chemotherapy in the management of cardiac tamponade secondary to disseminated breast carcinoma

SUNDARESWARAN RAMAKRISHNAN,* ANDREW J MARSHALL,† JOHN G PICKARD,* CHRISTOPHER J TYRRELL*

From the Departments of *Radiotherapy and Oncology, and †Cardiology, Plymouth General Hospital, Plymouth

Summary Three patients with cardiac tamponade secondary to disseminated breast carcinoma were treated by pericardiocentesis followed by systemic cytotoxic chemotherapy. This approach controlled pericardial effusion in all the patients and extended their survival.

Neoplastic cardiac tamponade is one of the emergencies of clinical oncology. It is a potential life threatening complication of disseminated malignant disease and can cause sudden death. The outlook in general is appalling, and despite treatment many patients survive for only 4–5 months.1 The choice of appropriate therapy can be difficult and the optimal management remains controversial. Vigorous treatment is often not suitable for patients who are debilitated with advanced cancer and haemodynamically compromised. None the less, in tamponade secondary to metastatic breast cancer, a vigorous approach is indicated because breast carcinoma is a potentially controllable disease for which there is effective systemic treatment. We present three cases of proven malignant cardiac tamponade secondary to disseminated breast carcinoma that we treated by pericardiocentesis followed by systemic cytotoxic chemotherapy.

Patients and methods

From 1981 to 1985, 722 new patients with breast carcinoma were seen at the Department of Radiotherapy and Oncology, Plymouth. In three (0.4%) patients clinically significant malignant pericardial effusion developed with symptoms and signs of cardiac tamponade. All three patients had disseminated breast carcinoma when tamponade developed. The diagnosis of cardiac tamponade was made on clinical examination, chest x ray, and electrocardiogram and was confirmed by echocardiography. All the patients underwent percutaneous pericardiocentesis for diagnostic and therapeutic purposes. Afterwards they were given systemic cytotoxic chemotherapy as outpatients and their response was monitored by following their clinical condition, serial chest x rays, and echocardiograms. The treatment was well tolerated with minimal side effects. In one of our patients early vinca neuropathy developed and there was no cardiotoxicity with doxorubicin in the dosage used (total dose less than 550 mg/m²). Survival was calculated from the date of pericardiocentesis to the date of death.

Results

The table shows the characteristics of our patients. All our patients were post-menopausal, the average age when cardiac tamponade developed was 58.3 years. The mean interval between diagnosis of breast carcinoma and development of tamponade was 32.7 months (range 0 to 70 months). None of our patients had previous cytotoxic chemotherapy and patients 1 and 3 had previous endocrine treatment. All our patients had evidence of metastatic disease at sites other than the pericardium when the effusion presented. The pericardial aspirate (mean volume 716 ml (range 150–1350 ml)) in all the cases was an exudate containing adenocarcinoma cells. The mean survival was 14.7 months (range 14 to 16 months). In all the

Requests for reprints to Dr S Ramakrishnan, Department of Radiotherapy and Oncology, Plymouth General Hospital, Freedom Fields, Plymouth, Devon PL4 7JJ.

Accepted for publication 16 May 1988
patients death was caused by progressive metastatic disease and the pericardial effusion did not recur.

Discussion

The accumulation of fluid in the pericardial space in patients with cardiac cancer is often not recognized until cardiac tamponade develops. The fluid usually reaccumulates rapidly after pericardiocentesis unless further definitive treatment is started. Such alternatives include the insertion of a pleuro-pericardial window, total or partial pericardiectomy, external radiotherapy, local instillation of a chemotherapeutic agent, local instillation of a sclerosing agent, and systemic chemotherapy.

Press and Livingston in a recent review of reported cases of malignant pericardial effusion and tamponade noted that no definitive conclusion can be made about optimal management because there are no controlled trials and many series are small with heterogeneous distribution of tumor types, varying criteria for clinical response, and concurrent treatments.

Reynolds and Byrne advocate pericardiocentesis followed by systemic chemotherapy for malignant pericardial effusion in carcinoma of the breast. Local control of pericardial effusion was achieved and survival was extended but their survival data were incomplete. Bitran et al managed their patients with a pleuropericardial window and systemic chemotherapy. They achieved a median survival of 26 months (range 17–50 months). Direct comparisons are difficult but we do not believe that the establishment of a pleuropericardial window is necessary because none of our patients had evidence of recurrence of pericardial effusion at the time of death. Smith et al in a review of all reported cases of malignant pericardial effusions up to 1974 concluded that patients treated conservatively without surgical intervention had a longer symptom-free interval than those given a pericardial window.

Although the survival of patients with neoplastic cardiac tamponade is in general limited, we believe that an active approach is warranted in those cases with tamponade secondary to breast carcinoma. Systemic cytotoxic chemotherapy after pericardiocentesis can achieve significant palliation in breast cancer, control pericardial effusion, prolong survival, with minimal toxicity, and give a good quality of life.

We thank Mrs Pauline Glover of the Radiotherapy Research Unit, for typing the paper. Mrs Glover is funded by the Cancer Research Campaign.

References

6 Davis S, Sharma SM, Blumberg ED, Kim CS. Intrapericardial tetracycline for the management of cardiac tamponade secondary to malignant pericar-


11 Haskell RJ, French WJ. Cardiac tamponade as the initial presentation in malignancy. *Chest* 1985;88:70–3.

Pericardiocentesis and systemic cytotoxic chemotherapy in the management of cardiac tamponade secondary to disseminated breast carcinoma.

S Ramakrishnan, A J Marshall, J G Pickard and C J Tyrrell

*Br Heart J* 1988 60: 162-164
doi: 10.1136/hrt.60.2.162

Updated information and services can be found at:
http://heart.bmj.com/content/60/2/162

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/